Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-09-23Clinical Trial Update: A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma [Phase 2]
A Phase 2 randomized study comparing AGS-16C3F versus Axitinib in metastatic renal cell carcinoma has completed and results are posted.
-
FDA approval · 2020-09-10FDA Approved: SORAFENIB TOSYLATE — Original Application (Mylan Pharmaceuticals Inc.)
The FDA approved a generic sorafenib tosylate product from Mylan under an original application. Sorafenib is indicated for hepatocellular ca…
-
CLINICAL_TRIALS trial_result · 2020-09-07Clinical Trial Update: Renal Adjuvant MultiPle Arm Randomised Trial [Phase 3]
Phase 3 randomized trial update for renal cell carcinoma in an adjuvant multi-arm study; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2020-09-01Clinical Trial Update: A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma [Phase 2]
Phase 2 study of tivozanib (AV-951) in renal cell carcinoma has completed with results posted.
-
FDA approval · 2020-08-17FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) by Novartis Pharmaceuticals Corporation. The approval updates…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-07-17FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2020-07-16Clinical Trial Update: A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) [Phase 1]
Phase 1 trial assessing pembrolizumab in renal cell cancer was terminated with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-07-10Clinical Trial Update: Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb [Phase 2]
Phase 2 translational study investigating molecular predictors of resistance to first-line pazopanib in metastatic renal cell carcinoma has …
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma [Phase 2]
Phase 2 study evaluating a PD-1 inhibitor in combination with autologous cell immunotherapy for metastatic renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2020-07-01Clinical Trial Update: AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib [Phase 2]
Phase 2 open-label study of AMG 386 combined with sunitinib in first-line or post-cytokine advanced renal cell carcinoma; study completed wi…
-
CLINICAL_TRIALS trial_result · 2020-06-22Clinical Trial Update: A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab [Phase 1]
Phase 1 study evaluating MEDI4736 (durvalumab) in combination with tremelimumab has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2020-06-17Clinical Trial Update: Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. [Phase 2]
Phase 2 trial comparing BIBF 1120 with sunitinib in renal cell carcinoma completed; results posted in 2020.
-
FDA approval · 2020-06-08FDA Approved: EVEROLIMUS — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s generic Everolimus under an Original Application, enabling the sale of a generic version of th…
-
FDA approval · 2020-06-02FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2020-05-28Clinical Trial Update: CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) [Phase 2]
Phase 2 trial update of CRLX101 (NLG207) in combination with bevacizumab for metastatic renal cell carcinoma compared to standard of care.
-
CLINICAL_TRIALS trial_result · 2020-05-12Clinical Trial Update: Sintilimab in FH-deficient Renal Cell Carcinoma [Phase 2]
Phase 2 clinical trial update for sintilimab in FH-deficient renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2020-04-29Clinical Trial Update: Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma [NA]
Clinical trial of PSMA-targeted 18F-DCFPyL PET/CT in evaluating renal cell carcinoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-04-08Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer [Phase 2]
Phase 2 trial results for Pazopanib hydrochloride in metastatic or recurrent kidney cancers have been posted after the study completed, incl…
-
CLINICAL_TRIALS trial_result · 2020-04-01Clinical Trial Update: Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer [Phase 2]
Phase 2 study evaluating the combination of interleukin-2 and pembrolizumab in metastatic renal cell carcinoma has completed with results po…
-
CLINICAL_TRIALS trial_result · 2020-03-13Clinical Trial Update: "Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
A retrospective study analyzed clinical factors associated with a high benefit of axitinib in metastatic renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2020-03-09Clinical Trial Update: Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer [Phase 1, Phase 2]
A completed Phase Ib/II trial evaluating interleukin-2 in combination with nivolumab for metastatic clear cell renal cell carcinoma; results…
-
CLINICAL_TRIALS trial_result · 2020-03-04Clinical Trial Update: Carfilzomib in Refractory Renal Cell Carcinoma (RCC) [Phase 2]
Phase 2 clinical trial update for carfilzomib in refractory renal cell carcinoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-27Clinical Trial Update: Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) [Phase 2]
Phase 2 trial update on sunitinib scheduling in metastatic renal cell carcinoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-20Clinical Trial Update: A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) [Phase 3]
Phase 3 trial comparing tivozanib hydrochloride to sorafenib in refractory advanced renal cell carcinoma has completed with results posted.
-
FDA approval · 2020-02-13FDA Approved: AFINITOR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Afinitor (everolimus) from Novartis Pharmaceuticals Corporation.